Drug Trial Radar · NCT02604914
A Sequential Two-Part, Open-Label Study in Healthy Male and Female Subjects
Last checked: Nov 19, 2026Latest source record: Jan 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
May 29, 2015
Primary completion
Jun 30, 2016
Study completion Jun 30, 2016
Sponsor
- Lead sponsor
- NeuroDerm Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Quotient Clinical
- First posted
- Nov 16, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
An Open-Label Study in Healthy Male and Female Subjects to Identify the Concentration that Provides Optimal Bioavailability of Levodopa Infused Subcutaneously via a Pump System; and to Compare the Bioavailability of Levodopa/Carbidopa Solution to that of Levodopa/Carbidopa Intestinal Gel (LCIG), Infused via a Naso-Jejunal Tube
Conditions
- Parkinson's Disease
Interventions
ND0612Drug
Subcutaneous solution
LCIGDrug
Intrajejunal Gel
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cmax (maximal plasma concentration) of CD for different doses of CDTime frame: 6 days
- AUC (area under the curve) of CD for different doses of CDTime frame: 6 days
- Cmax (maximal plasma concentration) of LD and CD for ND0612 vs. LCIGTime frame: 4 days
- AUC (area under the curve) of LD and CD for ND0612. LCIGTime frame: 4 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Quotient Clinical LTD
Ruddington, Nottingham, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.